logo conference-reports

Conference Reports

Educational funding by logo MSD Oncology

ASCO-SITC 2019—NKTR-262 + bempegaldesleukin does well in solid-tumor REVEAL

Data from the ongoing dose-escalation stage of a first-in-human phase 1/2 clinical study.